Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.63 |
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | FECH | P22830 | 1/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.63 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.63 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980652 | 1.00 | ERBB2 (0.63) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6174260 | 0.90 | ERBB2 (0.78) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6174252 | 0.90 | ERBB2 (0.78) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6174099 | 0.84 | ERBB2 (0.70) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6174092 | 0.84 | ERBB2 (0.70) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL4617369 | 0.83 | EGFR (0.67) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL4617364 | 0.83 | EGFR (0.67) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL2981258 | 0.81 | ERBB2 (0.49) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6177828 | 0.81 | ERBB2 (0.69) | ERBB2EGFRFECHCDK8MAP2K5 | |
| SCHEMBL6177836 | 0.81 | ERBB2 (0.69) | ERBB2EGFRFECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777032-B2 | N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7585975-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7501427-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ARRAY BIOPHARM, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 8/4885FECH 4456/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 8/4885FECH 4456/4885 |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | ERBB2 2/4885EGFR 8/4885FECH 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.